Spyre Therapeutics, Inc. announced on April 14, 2026, an underwriting agreement for the sale of 6,500,000 shares of common stock at $62.00 each, aiming to raise approximately $463.5 million for research and development. The underwriters also have a 30-day option to purchase an additional 975,000 shares, which they exercised on April 15, 2026.